@article{3047459,
    title = "EFFECT OF TRIMETHOPRIM-SULFAMETHOXAZOLE IN LANGERHANS CELL HISTIOCYTOSIS
- PRELIMINARY-OBSERVATIONS",
    author = "TZORTZATOUSTATHOPOULOU, F and XAIDARA, A and MIKRAKI, V and MOSCHOVI, M and and ARVANITIS, D and AGELOYIANNI, P and PRODROMOU, P",
    journal = "Medical and Pediatric Oncology",
    year = "1995",
    volume = "25",
    number = "2",
    pages = "74-78",
    publisher = "Wiley-Liss, Inc.",
    issn = "0098-1532, 1096-911X",
    doi = "10.1002/mpo.2950250205",
    keywords = "TRIMETHOPRIM-SULFAMETHOXAZOLE; LANGERHANS CELL HISTIOCYTOSIS;
THERAPEUTIC EFFECT",
    abstract = "Twenty-three children with Langerhans’ cell histiocytosis (LCH) have
been treated with trimethoprim-sulphamethoxazole CT-S) in a 4-year
period. The child ren are classified in two main groups according to the
extent of their disease. Group A includes 16 children with single system
disease and group B, seven children with multisystem disease. All
patients were treated for 4 weeks to 3 months. The results of treatment
are evaluated in terms of response in individual organs involved. All
children with single system disease had a good response to the drug.
Children with multisystem disease had a good response to some organs but
a poorer outcome for the lungs and for the blood. These patients did not
respond even to conventional chemotherapy. (C) 1995 Wiley-Liss, Inc."
}